Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal

Lead Drug Felzartamab Is Pipeline-In-A-Product

 
• By Mandy Jackson

Known for its efforts in neurology, Biogen has been looking to make somewhat safer bets in immunology as it seeks to diversify and may achieve that with HI-Bio’s Phase III-ready felzartamab. 

Isometric Business Success Concept. Entrepreneur business man leader. Searching for opportunities.
Biogen's HI-Bio buy merges immunology and rare disease capabilities • Source: Shutterstock

More from Deals

More from Business